Repligen (RGEN) Tops Q1 EPS by 20c; Lowers FY Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Repligen (RGEN) Tops Q1 EPS by 20c; Lowers FY Outlook

Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

April 27, 2022 7:30 AM EDT

Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency

Organic revenue growth of 44% for the quarter and base business growth of 37%

Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue

WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2022. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2022... More